The full management from first-line to third-line treatments in patients with her-2–negative advanced gastric cancer

HIGHLIGHTS

• who: Chunxiao Chang from the (IRCCS), Italy have published the research: The full management from first-line to third-line treatments in patients with Her-2u2013negative advanced gastric cancer, in the Journal: (JOURNAL)
• what: The authors retrospectively evaluated the treatment regimen of oxaliplatin plus oral fluoropyrimidine (S-1 or capecitabine or fluorouracil) in the first line, of nab-paclitaxel in the second line, and immune checkpoint inhibitors in the third line in patients with Her-2-negative advanced GC. The study has some regimen included capecitabine and oxaliplatin every 3 weeks or leucovorin, fluorouracil, and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.